An experimental trial of ubenimex (Bestatin®) combined with chemotherapy and radiotherapy in nude mice with human lung squamous cell carcinoma

International Journal of Immunotherapy

Volumn 15, Issue 3-4, 1999, Pages 107-114

  Kikuchi, K ^a   Kainami, Y ^a   Morohashi, H ^a   Nemoto, K ^a   Ekimoto, H ^a   Saino, T ^a   Miyamoto, T ^b   Abe, F ^a,c  

^a NIPPON KAYAKU CO LTD   (Japan)

^b NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^c NONE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BESTATIN; CISPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G; INTERLEUKIN 3; VINDESINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CONTROLLED STUDY; ERYTHROCYTE COUNT; FEMALE; LEUKOCYTE COUNT; LUNG SQUAMOUS CELL CARCINOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; THROMBOCYTE COUNT; TUMOR VOLUME;

EID: 0033500109     PISSN: 02559625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Tourani J.M., Timsit J.F., Delaisement C., et al. Two cycles of cisplatine-vindesine and radiotherapy for localized nonsmall cell carcinoma of the lung (stage III). Results of a prospective trial with 149 patients. Cancer, 65, 1472, 1990.
2. Fukuoka M., Takada M., Negoro S., et al. Randomized, controlled trial of combination therapy with ubenimex in inoperable lung cancer. Biotherapy, 3(6), 1504, 1989.
3. Furuse K., Fukuoka M., Genka K., et al. Double blind study of ubenimex (bestatin) against squamouse cell lung cancer - a multicenter cooperative study. Jpn. J. Cancer Chemother., 20(9), 1187, 1993.
4. Horiuchi K., Miyamoto T. Radioreductive effect of bestatin (ubenimex) in BALB/c mice. Int. J. Radiat. Biol., 62(1), 73, 1992.
5. Schorlemmer H.U., Bosslet K., Dickneite G., Lüben G., Sedlack H.H. Studies on the mechanisms of action of the immunomodulator bestatin in various screening test systems. Behring Inst. Mitt., 74, 157, 1984.
6. Umezawa H., Aoyagi T., Suda H., Hamada M., Takeuchi T. Bestatin, an inhibitor of aminopeptidase B, produced by actinomycetes. J. Antibiot., 29, 97, 1976.
7. Abe F., Shibuya K., Uchida M., et al. Effect of bestatin on syngeneic tumors in mice. Gann., 75, 89, 1984.
8. Abe F., Shibuya K., Uchida M., et al. Enhancement of antitumor effect of cytotoxic agents by bestatin. J. Antibiotics, 38(3), 411, 1985.
9. Abe F., Schneider M., Black P.L., Talmage J. E. Chemoimmunotherapy with cyclophosphamide and bestatin in experimental metastasis in mice. Cancer Immunol. Immunother., 29, 231, 1989.
10. Aoyagi K., Kainami Y., Morohashi H., et al. Antitumor activity of ubenimex in combination with chemotherapeutic agents (CDDP + VDS) against standard cell lines of human lung squamous cell carcinomas, LC-1 and Lu-61, transplanted in nude mice. Clinical Report, 28(11), 3487, 1994.
11. Tanaka R., Okada M., Kajimura N., et al. Triple paraneoplastic syndrome of hypercemia, leukocytosis and cachexia in two human tumor xenografts in nude mice. Jpn. J. Clin. Oncol., 26, 88, 1996.
12. Dawson K.B. Influence of the size of the admixture of irradiated cells on the Révész effect. Int. J. Radiat. Biol., 24(4), 413, 1973.
13. Blomgren H., Strender L. E., Edsmyr F. The influence of bestatin on the lymphoid system in the human. In: Umezawa H. (Eds.). "Small Molecular Immunomodifiers of Microbial Origin" Japan Scientific Societies Press, Tokyo, and Pergamon Press, Oxford, 1981, pp. 71-99.
14. Blomgren H., Edsmyr F., von Stedingk L.V., Wasserman J. Bestatin treatment enhances the recovery of radiation induced impairments of the immunological reactivity of the blood lymphocyte population in bladder cancer patients. Biomed. Pharmacother., 40, 50, 1986.
15. Kurauchi H., Onishi T. Study of radiotherapy with simultaneous administration of interferon using established human renal cell carcinoma heterotransplanted into nude mice. Tokyo Jikeikai Med. J. 103, 871, 1988.
16. Kasai S., Nagasawa H., Kuwasaka H., et al. TX-1877: Design, synthesis, and biological activities as a BRM-functional hypoxic cell radiosensitizer. Int. J. Radiat. Oncol. Biol. Phys., 42(4), 799, 1998.
17. Horii T. Combination effects of radiotherapy and bestatin on C3H/He mouse N-fibrosarcoma. J. Kyoto Pref. Univ. Med., 100(11), 1051, 1991.